Retinitis pigmentosa (RP) is a neurodegenerative disorder that causes irreversible vision loss in over 1.5 million individuals world-wide. In this study, we demonstrate that a metabolic reprogramming can treat degeneration in a Pde6β preclinical model of RP. Pyruvate kinase M2 (PKM2) is a glycolytic enzyme that transfers phosphate from phosphoenolpyruvate (PEP) to adenosine diphosphate (ADP), promoting glucose catabolism. Ablation of PKM2 resulted in enhanced photoreceptor survival and function in Pde6β-mutated mice compared with those without ablation. Electroretinogram (ERG) analyses revealed that the maximum b-wave is on average greater in Pkm2 knockout mice than in mice with Pkm2 intact. These rescue phenotypes from Pkm2 ablation in a preclinical model of RP indicate that a metabolome reprogramming may be useful in treating RP.
INTRODUCTION
Retinal degenerative diseases affect nine million Americans.1,2 Among these conditions, retinitis pigmentosa (RP) is the most devastating in terms of severity and prevalence, making it one of the most common cause of irreversible vision loss. Associated with more than 80 genes, RP is a heterogeneous condition that is characterized by rod photoreceptor degeneration followed by secondary cone death,3-5 leading to night blindness, tunnel vision, and eventually, complete blindness. Current treatment options include the use of retinal prostheses6,7 or RPE65 gene therapy.8-10 However, these strategies are only applicable for patients with end-stage RP or those carrying RPE65 mutations,11 respectively. At the same time, clinical gene therapy trials for RP primarily involve augmentation or repair of a single gene, which even if successful, would only be applicable to patients carrying those specific gene mutations. 12 More recently, insight into the genetic etiologies of retinal degeneration has found that photoreceptor death may be linked to apoptotic factors,13,14 metabolic derregualation,3,15 and oxidative stress. 16, 17 Targeting any one of these pathways, in turn, may offer an alternative gene non-specific therapy. As of yet, however, there is no effective therapeutic option for RP and other retinal degenerative diseases.
Punzo et al. studied gene expression changes in RP mouse models by linking mutations in rodspecific genes to their corresponding cellular processes.3 Microarray analysis of samples collected at the onset of cone death revealed that 35% of annotated genes were involved in cellular metabolism, implicating metabolic processes in disease pathogenesis. To follow-up, Punzo et al. and Zhang et al. focused on the insulin/mTOR pathway and found that enhanced anabolic flux and lactate levels indeed slowed rod-cone degeneration. 18, 19 Consistently, rodspecific knockout of sirtuin 6, a transcriptional repressor of glycolytic enzymes, enhanced glycolysis, rod preservation, and photoreceptor function.20 Augmenting anabolism in rod photoreceptors could therefore serve as a potential treatment for RP.
One identified key regulator of cellular metabolism is pyruvate kinase M2 (PKM2), a critical catalyst for the final step of glycolysis that aids in the transfer of a phosphate group from phosphoenolpyruvate (PEP) to adenosine diphosphate (ADP). PKM2 is allosterically regulated so that it exists in two forms: an inactive dimer with low binding affinity to PEP and an active tetramer form with high affinity to PEP.21 When phosphorylated PKM2 is in its inactive form, less consumption of PEP occurs, resulting in higher PEP levels. This has been found to activate the pentose phosphate pathway (PPP), a process that produces glycolytic intermediates for nucleotide and lipid synthesis. As a result, when PKM2 is inhibited, subsequently, PEP accumulates, promoting the PPP.22 PKM2's ability to regulate the production of glycolytic intermediates, which is essential for photoreceptor cells, makes it an attractive target to elucidate the role of glycolysis in rod and cone health. Previous studies have already found that PKM2 ablation enhances long-term photoreceptor survival in retinal detachment models, suggesting that PKM2 ablation may offer photoreceptor protection against acute external retinal stress.23
More recently, PKM2 has been implicated in the regulation of PDE6β,24 a phototransduction enzyme complex that blocks Ca+2 influx by closing cyclic nucleotide-gated (CNG) channels through cGMP hydrolysis. PDE6 is a heterotetramer with two catalytic subunits (PDE6A and PDE6B) and mutations in either can disrupt function similarly and yield identical downstream effects.25-37 One in 10
Americans carries a recessive RP allele,27,38 and 10% of those alleles confer mutations in one of the two subunits of phosphodiesterase-6 (Pde6), accounting for 5-8% of all RP cases. 27, 28 As such, PKM2 may very well also play a role in preserving photoreceptors from inherited retinal diseases, which represent internal sources of retinal stress.
In this report, we expand on previous findings by investigating the functional and morphological contributions of rod-specific Pkm2 ablation in inherited retinal degeneration with a tamoxifeninducible Pkm2 knockout Pde6β H620Q/H620QRP model. We hypothesize that Pkm2 knockout in the rods will promote photoreceptor anabolism and, in doing so, preserve rod and cone survival and function, delaying retinal degeneration.
RESULTS

Deletion of Pkm2 in Pde6βH620Q/H620Q mice
To evaluate whether and, if so, how PKM2 plays a role in rod metabolome reprogramming, we used the tamoxifen inducible Cre recombinase system to ablate Pkm2 in a slow progressing Pde6β RP model: Pde6βH620Q/H620Q. 29 Rod selective ablation of Pkm2 significantly reduced total PKM2 levels in Pde6βH620Q/H620Q Pkm2-/-mice compared to wild-type mice ( Fig. 1 ).
Accordingly, there was also a reduction in phosphorylated PKM2 in Pde6βH620Q/H620Q Pkm2-/mice, suggesting a decrease in the catalytic activity of PKM2. It is important to note, however, that experimental mice retained detectable levels of PKM2 and P-PKM2, shown in Figure 1 , due to the conditional nature of the rod-specific Pkm2 knockout.
Deletion of Pkm2 in Pde6βH620Q/H620Q mice improved retinal morphology
Subsequently, we gauged the survival impact of Pkm2 ablation on retinal morphology using histology to compare the morphology of the outer nuclear layer (ONL), inner segment (IS), and outer segment (OS). Pde6βH620Q/H620Q Pkm2+/+ mice exhibited degenerated photoreceptors within ONL while thin ONLs while Pde6βH620Q/H620Q Pkm2-/-mice had comparatively more cells ( Fig.   2A ). Similar trends were observed for IS/OS layers-compared to their isogenic controls, treated mice exhibited greater IS/OS thickness throughout the retina ( Fig. 2A, B ). Strikingly, all the layers in the experimental mice were still noticeably thinner than those in wild-type mice.
Overall, ablation of Pkm2 may be able to preserve but not completely rescue photoreceptor survival and preserved photoreceptors.
Deletion of Pkm2 in Pde6βH620Q/H620Q mice improved retinal function
At four weeks post-treatment, Pde6βH620Q/H620Q Pkm2-/-mice exhibited an enhanced scotopic bwave amplitude compared to Pde6βH620Q/H620Q Pkm2+/+ (Fig. 3A ), suggesting greater rod preservation. In contrast, there was no significant difference in the mixed and photopic b-wave amplitudes between the two groups, indicating that cone preservation remained approximately the same. At eight weeks post injection, all b-wave amplitudes in both groups declined considerably. Notably, Pde6βH620Q/H620Q Pkm2-/-mice maintained significantly higher scotopic, maximal, and photopic b-waves (p<0.05) compared to Pde6βH620Q/H620Q Pkm2+/+ mice, indicating a more robust preservation in cone and rod function. Consistently, statistical analysis revealed a significant correlation (p<0.05) between the value of the maximal b-wave and presence of tamoxifen treatment. These results reveal that rod-specific Pkm2 ablation improved photoreceptor vitality in Pde6β-mutated mice.
DISCUSSION
In this report, we demonstrated that rod-specific ablation of Pkm2 can rescue both cone and rod photoreceptor degeneration. Using both structural and functional assays, we are the first to use a preclinical RP model to study the effects of Pkm2 knockout. These findings further advance the work done by Chinchore et al. who first discovered that PKM2 mediates Warburg glycolysis in healthy photoreceptors, 39 Here, we advance the current understanding of PKM2 by uncovering its genetic contributions in inherited retinal degeneration. Notably, rod-specific Pkm2 knockout noticeably increases the thickness of the ONL and IS/OS layers, indicating better photoreceptor survival. ERG functional analysis was consistent with anatomical findings and revealed that Pkm2 ablation also improved both cone and rod function significantly. These results suggest that PKM2 deficiency was indeed able to rescue retinal degeneration. As proposed by Wubben et al., the rescue phenotypes may be a direct result of enhancing catabolism and therefore ATP output in photoreceptors. This explanation, however, handles photoreceptors as isolated systems whose metabolism works in a cell autonomous manner. In this paper, we propose an alternative yet complementary framework that aims to consider PKM's role in photoreceptors in relation to the RPE, offering insight into how it may regulate the delicate metabolic dynamic between the two.
One of the first evidences of a metabolic coupling was described by Punzo, et al., who found that the disruptions in the insulin/mTOR signaling pathway coincided with cone death in four mouse models for RP.3 Strikingly, systemic supplementation of insulin was able to rescue cone death, suggesting that photoreceptor death in RP progresses in a cell non-autonomous manner.
Subsequent studies characterizing the nature of this relationship have led to the emergence of the "metabolic coupling hypothesis", which proposes that metabolic imbalances leads to cone photoreceptor death via glucose deprivation.3,19,40 Normally, photoreceptors take up glucose from the retinal pigment epithelium (RPE) and convert it into fat and lactate,41 which are subsequently used to drive essential processes throughout the retina. In photoreceptors, the steady production of protein and lipids drives the daily disposal and regeneration of the OS. 42, 43 In contrast, the RPE consumes the generated lactate as the carbon source for the tricarboxylic acid (TCA) cycle,39,44,45 saving glucose for photoreceptors. In RP, however, impaired photoexcitation prevents diseased rods from generating sufficient amounts of lipid and lactate. This not only stagnates OS biogenesis but also prompts the RPE to use glucose through anabolism. The depletion of glucose by the RPE, in turn, deprives photoreceptors of nourishment and leads to prevalent rod and subsequent cone deaththe hallmark of late-stage RP.
In light of this framework, the rescued phenotypes indicate a rejuvenation of the disrupted metabolic dynamic within the diseased retina. Previous studies have shown that phosphorylated PKM2 leads to the accumulation of 2-phosphoenolpyruvate and the subsequent activation of the anabolic PPP pathway. 24 As such, PKM2 deficiency may elevate anabolism and the synthesis of proteins and lipids, fueling the regeneration of the OS and promoting oxidative phosphorylation in the RPE. This metabolic reprogramming, in turn, restores a steady supply of glucose to the diseased photoreceptors, precluding the need to optimize metabolism. As a result, the photoreceptors return to a preferred anabolic state and employ aerobic glycolysis to satisfy their ATP needs, promoting photoreceptor health and function. It is important to note that this model is not necessarily incompatible with the notion of catabolism-mediated photoreceptor survival as described by Wubben et al. Roughly 80%-90% of the glucose in photoreceptors is metabolized through aerobic glycolysis, indicating that a small, but significant, fraction still undergoes catabolism. While we highlight that different anabolic processes can provide photoreceptors with both the raw materials and energy to survive and function, it is possible that a certain level of catabolism is needed to sufficiently meet the high energy demands of a healthy photoreceptor and counteract the insult from metabolic imbalance.
Another notable finding is that despite the significant improvements in both retinal morphology and function, PKM2 ablation was not able to induce a complete rescue in either case. Alternatively, it is likely that retinal degeneration impacts a wide range of independent metabolic pathways. As such, PKM2 ablation is only able to affect PKM2-dependent processes, leading to a partial but not complete rescue of the deleterious phenotypes.
Although this study identifies PKM2 as one of the major players in slowing down retinal degeneration, future studies identifying specific molecules and pathways would be beneficial in understanding the mechanism of this relationship. Wubben et al. offered critical insight into the specific genes impacted by PKM2 ablation in the retina. 23 Expanding their analysis to include gene expression changes in the RPE offers a quantitative way to not only support PKM2's role in regulating metabolic coupling, but also track the metabolic changes over time. Another promising direction for research is to characterize PKM1's role and whether its interaction with PKM2 is conserved in inherited retinal disease. This question is important as it would clarify whether PKM1 indeed acts as an antagonistic regulator of anabolic influx that may limit the impact of metabolic reprogramming. Other potential directions include tuberous sclerosis complex 1 (TSC1), an mTOR inhibitor, and hypoxia inducible factor-1α (HIF-1α), a transcription factor responsible for oxygen consumption regulation. In our earlier studies, we showed that both of these molecules are linked to photoreceptor rescue from metabolic reprogramming.19,46 Moreover, separate groups have found that PKM2 interacts directly with mTOR and HIF-1α, hinting towards possible mechanistic pathways. [47] [48] [49] One important consideration is that Rajala et al. have shown in vitro evidence that PKM2 may regulate transcriptional activity through the PDE6β promoter. 24 This finding suggests that PKM2 knockout may have promoted photoreceptor health by working directly with Pde6β, which would indicate that the beneficial effects are specific to Pde6β deficiency. As such, we highlight the need to use a different RP model to evaluate whether the rescue phenotypes from PKM2 ablation are in fact a result of its role in a gene non-specific metabolic pathway.
Current CRISPR/Cas9-based gene therapy relies on a gene-and mutation-specific approach.
Given that over 80 genes have been implicated in the development of RP, this strategy is impractical as it is not amenable to large-scale production or treatment. Here, we have demonstrated that PKM2 ablation offers 6 equivalent years of improved eyesight in our RP model,50 suggesting that elevations in rod-specific anabolism can offer protection against degeneration in a non-gene-specific manner. Importantly, the metabolic pathways highlighted in this study are common to not only retinal degeneration, but also neurodegenerative conditions including Alzheimer's Disease. 51, 52 As such, reprogramming the metabolism of a terminally differentiated neuron towards a more anabolic state may offer a universal, gene non-specific treatment for multiple neurodegenerative conditions. The classical function of PKM2 as a catalyst for the final step in glycolysis lies at the heart of metabolic regulation. Therefore, a deeper understanding of its role in coupling the dynamic metabolisms of the retina and RPE may offer critical insight into and advancement towards the development of gene non-specific therapeutics. Such a strategy can then be used synergistically with gene supplementation therapy to optimize efficacy.
MATERIALS AND METHODS
Animals
All mice were maintained in the Columbia University Pathogen-free Eye Institute Annex Animal Abcam), and rabbit anti-phospho-PKM2 (1:1000; #3827S; Cell Signaling Technology). The following day, the membrane was washed in 0.5% PBST (500 μl Tween-20 in 1,000 ml PBS), and subsequently incubated in mouse monoclonal anti-rabbit IgG-HRP antibody (1:2000; ab99697; Abcam) and rabbit anti-mouse IgG-HRP antibody (1:2,000; sc-358914; Santa Cruz Biotechnology Inc.). Chemiluminescence (EMD Millipore) was detected using Biomax film (Kodak), and PKM2, P-PKM2, and actin levels were then quantified.
Histology
As described by Velez, et al., Eyes were enucleated from euthanized mice, by following along the limbus to create a puncture at the 12 o'clock position. 56 Each eye was then placed in a solution of 1:2x Karnovsky fixative for 24 hours. Following fixation, eyes underwent a saline wash and then dehydration to be embedded in paraffin. Afterwards, hematoxylin and eosin were used to stain paraffin sections, which were then examined by light microscopy.
Rod OS Measurement
Following euthanasia, the eye was enucleated followed by cornea and lens dissection and vitreous removal. At every 100 microns from the optic nerve, Rod OS was measured using a Image J (NIH, Bethesda)e. Measurements were taken for segments 500 microns away from the optic nerve on both eyes. All procedures were done in accordance with previously established IACUC guidelines. 
ERG
Statistical Analysis
Using the ERG results, the maximal b-wave wave of each eye was taken and used to fit a linear model using generalized least squares. This method of regression was chosen because of the correlation between the eyes of each mouse and to account for unequal variance between treated and non-treated mice. 
